Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Controlled Phase 3 Study of Oral Pacritinib vERsus BeSt Available Therapy in PatIentS with Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post Essential Thrombocythemia Myelofibrosis

Trial Profile

A Randomized Controlled Phase 3 Study of Oral Pacritinib vERsus BeSt Available Therapy in PatIentS with Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post Essential Thrombocythemia Myelofibrosis

Discontinued
Phase of Trial: Phase III

Latest Information Update: 04 Dec 2018

At a glance

  • Drugs Pacritinib (Primary)
  • Indications Myelofibrosis
  • Focus Registrational; Therapeutic Use
  • Acronyms PERSIST-1
  • Sponsors Cell Therapeutics; CTI BioPharma
  • Most Recent Events

    • 04 Dec 2018 Results of pooled analysis of all available TSS data from PERSIST 1 and PERSIST 2 was undertaken to further evaluate TSS response presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
    • 03 Aug 2017 This trial has been completed in Germany (End date:30-11-2016)
    • 13 Jul 2017 According to a CTI BioPharma media release, the European Medicines Agency (EMA) has validated the MAA for pacritinib for the treatment of patients with myelofibrosis who have thrombocytopenia (platelet counts less than 100,000 per microliter). The MAA is primarily supported by data from two phase III clinical trials, PERSIST-1 and PERSIST-2.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top